James P OBrien
Overview
Explore the profile of James P OBrien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koudelka A, Buchan G, Cechova V, OBrien J, Stevenson E, Uvalle C, et al.
J Lipid Res
. 2024 Nov;
66(1):100705.
PMID: 39566850
The enzymatic oxidation of arachidonic acid is proposed to yield trihydroxytetraene species (termed lipoxins) that resolve inflammation via ligand activation of the formyl peptide receptor, FPR2. While cell and murine...
2.
Koudelka A, Buchan G, Cechova V, OBrien J, Liu H, Woodcock S, et al.
bioRxiv
. 2024 Feb;
PMID: 38370667
The enzymatic oxidation of arachidonic acid is proposed to yield trihydroxytetraene species (termed lipoxins) that resolve inflammation via ligand activation of the formyl peptide receptor, FPR2. While cell and murine...
3.
Davidson S, Schmidt D, Heyman J, OBrien J, Liu A, Israelsen W, et al.
Cancer Res
. 2022 May;
82(13):2403-2416.
PMID: 35584006
Differential expression of PKM1 and PKM2 impacts prostate tumorigenesis and suggests a potential therapeutic vulnerability in prostate cancer.
4.
Manni M, Heinrich V, Buchan G, OBrien J, Uvalle C, Cechova V, et al.
Sci Rep
. 2021 Sep;
11(1):17788.
PMID: 34493738
Bile acid profiles are altered in obese individuals with asthma. Thus, we sought to better understand how obesity-related systemic changes contribute to lung pathophysiology. We also test the therapeutic potential...
5.
Marrocco A, Frawley K, Pearce L, Peterson J, OBrien J, Mullett S, et al.
J Immunol
. 2021 Aug;
207(6):1627-1640.
PMID: 34433619
Silicosis is a lethal pneumoconiosis for which no therapy is available. Silicosis is a global threat, and more than 2.2 million people per year are exposed to silica in the...
6.
Yochum Z, Cades J, Wang H, Chatterjee S, Simons B, OBrien J, et al.
Oncogene
. 2018 Sep;
38(5):656-670.
PMID: 30171258
Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de...
7.
Davidson S, Papagiannakopoulos T, Olenchock B, Heyman J, Keibler M, Luengo A, et al.
Cell Metab
. 2016 Feb;
23(3):517-28.
PMID: 26853747
Cultured cells convert glucose to lactate, and glutamine is the major source of tricarboxylic acid (TCA)-cycle carbon, but whether the same metabolic phenotype is found in tumors is less studied....
8.
Hong D, Kurzrock R, Falchook G, Andresen C, Kwak J, Ren M, et al.
Oncotarget
. 2015 Oct;
6(40):43127-34.
PMID: 26503473
Objective And Methods: In this phase 1b study, patients with stage 4 or unresectable stage 3 melanoma were treated with escalating doses of lenvatinib (once daily) and temozolomide (TMZ) (days...
9.
Schlumberger M, Jarzab B, Cabanillas M, Robinson B, Pacini F, Ball D, et al.
Clin Cancer Res
. 2015 Aug;
22(1):44-53.
PMID: 26311725
Purpose: Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC). Experimental Design: Fifty-nine patients...
10.
Hong D, Kurzrock R, Wheler J, Naing A, Falchook G, Fu S, et al.
Clin Cancer Res
. 2015 Jul;
21(21):4801-10.
PMID: 26169970
Purpose: This "3+3" phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors. Experimental Design: Ascending doses of lenvatinib...